Bio-Rad Laboratories, Inc. (BIO) Yield on Cost (YOC): N/A
The yield on cost (YOC) for Bio-Rad Laboratories, Inc. (BIO) is N/A.
BIO Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Bio-Rad Laboratories, Inc. (BIO) based on your custom cost basis.
Starting Yield
0.67%
Ending YOC
2.13%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 0.67% | $0.00 |
| Year 1 | $2.16 | +8.00% | 0.73% | $2.16 |
| Year 2 | $2.33 | +8.00% | 0.79% | $4.49 |
| Year 3 | $2.52 | +8.00% | 0.85% | $7.01 |
| Year 4 | $2.72 | +8.00% | 0.92% | $9.73 |
| Year 5 | $2.94 | +8.00% | 0.99% | $12.67 |
| Year 6 | $3.17 | +8.00% | 1.07% | $15.85 |
| Year 7 | $3.43 | +8.00% | 1.15% | $19.27 |
| Year 8 | $3.70 | +8.00% | 1.25% | $22.98 |
| Year 9 | $4.00 | +8.00% | 1.35% | $26.97 |
| Year 10 | $4.32 | +8.00% | 1.45% | $31.29 |
| Year 11 | $4.66 | +8.00% | 1.57% | $35.95 |
| Year 12 | $5.04 | +8.00% | 1.69% | $40.99 |
| Year 13 | $5.44 | +8.00% | 1.83% | $46.43 |
| Year 14 | $5.87 | +8.00% | 1.98% | $52.30 |
| Year 15 | $6.34 | +8.00% | 2.13% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Bio-Rad Laboratories, Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz